강박장애에서 성별에 따른 임상양상 차이

홍현주¹·구민성²·김찬형^{3,4}·서호석⁵·천근아²·남윤영³·박성혁³ ,¹ ,⁴ 5

ABSTRACT

Gender-Related Clinical Differences in Obsessive-Compulsive Disorder

Hyun Ju Hong, MD,¹ Min-Seong Koo, MD,² Chan-Hyung Kim, MD, PhD,^{3,4} Ho-Suk Suh, MD,⁵ Keun-Ah Cheon, MD,² Yoon Young Nam, MD³ and Sung Hyuck Park, MD³

¹Department of Neuropsychiatry, Hallym University College of Medicine, Chuncheon, ²Department of Psychiatry, College of Medicine, Kwandong University, Goyang, ³Department of Psychiatry, Yonsei University College of Medicine, Seoul, ⁴Institute of Behavioral Science in Medicine, Seoul, ⁵Department of Psychiatry, Pochon CHA University College of Medicine, Pocheon, Korea

Objective: Some reports have shown the gender-related clinical differences in Obsessive-compulsive disorder (OCD), but no study has yet been done in Korea. The purpose of this study was to investigate the gender-related differences of clinical features in the obsessive-compulsive patients in Korea. Methods: Two hundred forty nine patients with OCD were included in this study; 180 subjects were male and 69 subjects were female. The two groups were analyzed in terms of demographic data including clinical variable, Y-BOCS (Yale-Brown Obsessive Compulsive Scale) scores, clinical course and treatment response. Results: We found the earlier age at onset of OC symptoms in males and the more frequent washing and somatization type in female. There were no gender difference in comorbidity, clinical course and the treatment response. Conclusion: We could observe some of the gender-related clinical differences in Korean OCD patients. The further studies would be required to evaluate the gender difference in the long-term clinical course and therapeutic response of Korean OCD patients. (Korean J Psychopharmacol 2005;16(4):301-308)

KEY WORDS: Gender difference · Obsessive-compulsive disorder · Clinical feature.

가 서 론 .1)

1.5 : 1

2004 5 교신저자: , 135 - 720 146 - 92

: (02) 3497 - 3340 · : (02) 3462 - 4304 E - mail : spr88@yumc.yonsei.ac.kr

| . 3- | - 5) | | 2) DSM - ²⁾ | | , 3) |
|-----------|-------------|-------------|------------------------|-------------------|------------------------|
| | | 가 | | 12 | 가 , |
| | | | 4) | 가 | |
| 가 | 1,4,6 - 10) | | , | 1) | |
| 가 | • | | · | ., | , 2) |
| 71 | • | | , | | , 2) |
| | | | , | , 가 | , |
| | | , , | 0) | 71 | , |
| , | 8,9,11,12) | | 3) | • | |
| • | | 1,4,8,9,13) | 2. 임상 양상 및 | 증상의 평가 | |
| | 가 | | 가 | | |
| | 4) | . 6) | , | С | SM - |
| | 1) | 8) | , | | |
| | 가 | | | | 2 |
| 1,6,14) | | , | 가 | フ | |
| | 35.7% | 가 | - 1 | - 1 | |
| 가 | 13.2% | .1) | | | • |
| | | | (Vale - Brown Ob | neassiva Compu | Isive Scale : Y - BO- |
| | | | | al Global Impre | |
| (serotoni | n marker) | .15) | 8 | | 가 . |
| | | | C |) 12 / | |
| 가 | | | 3. 약물치료 | | |
| | | | flu | uoxetine, sertral | line, paroxetine, clo- |
| | , | clomipra- | mipramine | | |
| mine | | 16) | | | |
| | | | benzodiazepine(a | alprazolam, clona | azepam, lorazepam), |
| | | | trazodone, risper | ridone, olanzapir | ne 가 |
| | | | | 8 12 | 2 |
| | | | | 1 | |
| | | | | | |
| | | | 4. 자료분석 | | |
| | 연구대상 및 방 | 법 | | | , |
| | | _ | student t | - test | |
| 1. 연구대상 | | | | | , |
| | 1998 9 200 | 2 8 | | Chi - square tes | |
| | | | | | 8 , 12 |
| | | (SRI) | Y - BOCS | repeated m | neasure 2 - way AN- |
| | 249 | | OVA | • | p<0.05 |
| | 1) 17 | 55 . | | SPSS | WIN 10.5 . |

Table 1. Treatment medications in male and female patients

| | | 8 th weeks | 12 th weeks |
|--------|------------------------------|--|---|
| | Principal drugs [†] | Number of patients (mean dosage : mg/day ± SD) | Number of patients (mean dosage : mg/day ± SD) |
| | Fluoxetine | 112 (68.4 ± 14.3) | 116 (72.3 ± 13.4) |
| | Sertraline | 21 (149.4 ± 26.2) | 16 (136.6 ± 24.4) |
| Male | Paroxetine | 33 (44.1 ± 11.1) | 36 (52.4 ± 15.6) |
| | Clomipramine | 12 (251.6 ± 82.4) | 11 (243.9 ± 65.7) |
| | Others* | 2 | 1 |
| | Fluoxetine | 34 (62.1 ± 14.2) | 32 (66.3 ± 10.7) |
| Female | Sertraline | 13 (122.5 ± 23.8) | 15 (116.6 ± 24.9) |
| | Paroxetine | 16 (41.6 ± 11.2) | 17 (43.1 ± 11.2) |
| | Clomipramine | $5(205.6 \pm 74.2)$ | 4 (243.9 ± 65.7) |
| | Others* | 1 | 1 |

Table 2. Demographic and clinical characteristics of the patients with obsessive compulsive disorder

| Variables | Total | Male (N=180) | Female (N=69) |
|-------------------------------|-----------------|-----------------|--------------------|
| Age* (year) | 30.78 ± 11.53 | 28.37 ± 10.83 | 37.12 ± 12.12 |
| Onset age [†] (year) | 21.42 ± 9.69 | 19.42 ± 8.16 | 25.55 ± 11.39 |
| Duration of illness (months) | 102.21 ± 82.05 | 102.21 ± 84.14 | 102.20 ± 77.26 |
| Y-BOCS baseline | 29.22 ± 6.29 | 28.91 ± 6.33 | 30.02 ± 6.17 |
| CGI-S baseline | 5.49 ± 0.95 | 5.42 ± 0.94 | 5.56 ± 0.96 |

Y-BOCS: Yale-Brown Obsessive Compulsive Scale, CGI-S: Clinical Global Impressions-Severity

Table 3. Types of Obsessive compulsive disorder in male and female patients

| Turoos | Number of patients (97) | Male (%) | Famoula (97) | Chi-square test* | | |
|------------------------|-------------------------|-----------|--------------|------------------|---------|--|
| Types | Number of patients (%) | | Female (%) - | 2 (df=1) | p value | |
| Compulsions | | | | | _ | |
| Checking | 60 (24.1) | 47 (26.1) | 13 (18.8) | 0.03 | 0.85 | |
| Counting | 13 (5.2) | 10 (5.5) | 3 (4.3) | 0.14 | 0.71 | |
| Washing | 59 (23.7) | 34 (18.9) | 25 (36.2) | 12.35 | <0.01 | |
| Symmetry and precision | 17 (6.8) | 13 (7.2) | 4 (5.8) | 0.15 | 0.69 | |
| Hoarding | 12 (4.8) | 9 (5.0) | 3 (4.3) | 0.58 | 0.61 | |
| Need to ask or confess | 11 (4.4) | 8 (4.4) | 3 (4.3) | 0.01 | 0.94 | |
| Obsessions | | | | | | |
| Pathologic doubt | 28 (11.2) | 22 (12.2) | 6 (8.7) | 1.21 | 0.09 | |
| Aggression | 15 (6.0) | 12 (6.7) | 3 (4.3) | 0.47 | 0.49 | |
| Sexual | 9 (3.6) | 7 (3.9) | 2 (2.9) | 0.69 | 0.87 | |
| Somatization | 12 (4.8) | 8 (4.4) | 4 (5.8) | 3.45 | 0.04 | |
| Contamination | 3 (1.2) | 2 (1.1) | 1 (1.5) | 0.12 | 0.81 | |
| Need for symmetry | 6 (2.4) | 5 (2.8) | 1 (1.5) | 0.48 | 0.46 | |
| Others | 4 (1.6) | 3 (1.7) | 1 (1.5) | | | |
| Totals | 249 | 180 | 69 | | | |

^{*:} Yates' continuity correction applied in case of the number in each cell was less than 5

^{*:} antipsychotics (risperidone and olanzapine)
†: means the drug used chiefly at the week regardless of combinations with other drugs

^{*:} student t-test: t = 12.3, df = 1, p < 0.01

^{† :} student t-test : t=8.7, df=1, p<0.01

Table 4. Comorbidity of male and female obsessive compulsive disorder patients*

| Disa cas setitios | Conneifia disenses | T-1-1 (07) | M - I - (07) | Fama ala (97) | Chi-square test † | |
|------------------------|-------------------------|------------------|--------------|---------------|---------------------|---------|
| Disease entities | Specific diseases | Total number (%) | Male (%) | Female (%) | ² (df=1) | p value |
| | Depression | 72 (28.9) | 51 (28.3) | 21 (30.4) | | |
| | Dysthymia | 3 (1.2) | 2 (1.1) | 1 (1.5) | | |
| Mood disorders | Bipolar disorder | 3 (1.2) | 3 (1.7) | 0 | | |
| | Other emotional problem | 2 (0.8) | 1 (0.5) | 1 (1.5) | | |
| | Subtotal | 80 (32.1) | 57 (31.7) | 24 (34.8) | 0.10 | 0.91 |
| | Panic disorder | 7 (2.8) | 4 (2.2) | 3 (4.3) | | |
| | Hypochodriasis | 6 (2.4) | 3 (1.7) | 3 (4.3) | | |
| Anxiety disorders | Social phobia | 15 (6.0) | 11 (6.1) | 4 (5.7) | | |
| All Alony disorders | GAD | 3 (1.2) | 3 (1.7) | 0 | | |
| | Other anxiety disorder | 8 (3.2) | 6 (3.3) | 2 (2.9) | | |
| | Subtotal | 39 (15.7) | 27 (15.0) | 12 (17.4) | 0.11 | 0.86 |
| Somatoform disorders | Somatization disorder | 3 (1.2) | 2 (1.1) | 1 (1.5) | 0.12 | 0.81 |
| | OCPD | 30 (12.0) | 22 (12.2) | 8 (11.6) | | |
| | Avoidant PD | 15 (6.0) | 12 (6.7) | 3 (4.3) | | |
| | Schizoid PD | 3 (1.2) | 3 (1.7) | 0 | | |
| Personality disorders | Borderline PD | 5 (2.0) | 4 (2.2) | 1 (1.5) | | |
| r ersonality disorders | Histrionic PD | 3 (1.2) | 2 (1.1) | 2 (2.9) | | |
| | Antisocial PD | 2 (0.8) | 2 (1.1) | 0 | | |
| | Schizotypal PD | 3 (1.2) | 3 (1.7) | 0 | | |
| | Subtotal | 61 (24.5) | 48 (26.7) | 14 (20.3) | 0.15 | 0.69 |
| | ADHD | 4 (1.6) | 4 (2.2) | 0 | | |
| Child onset diseases | Tic disorder | 18 (7.2) | 16 (8.9) | 2 (2.9) | | |
| | Subtotal | 22 (8.8) | 20 (11.1) | 2 (2.9) | 2.98 | 0.06 |
| Psychotic disorder | Psychotic disorder NOS | 15 (6.0) | 13 (7.2) | 2 (2.9) | 0.69 | 0.87 |
| Others | Alcohol dependence | 3 (1.2) | 3 (1.7) | 0 | | |
| | PMS | 1 (0.4) | 0 | 1 (1.5) | | |

^{*:} some patients had multiple comorbid disorders

GAD: Generalized Anxiety Disorder, OCPD: Obsessive Compulsive Personality Disorder, ADHD: Attention Deficit Hyperactivity Disorder, PMD: Premenstrual Disorder

^{† :} Yates' continuity correction applied in case of the number in each cell was less than 5

3 1) (episodic) 2) (chronic) , 3) (Chi - square test: = 12.35, p<0.01, 6 : 2 =3.45, p=0.04)(3). 6 가 31.7% 가 26.7%, 15.0%, 11.1%, 7.2%, 86 (34.3%), 106 1.1% (42.7%)57 (22.9%) 가 34.8%, 20.3%, 17.4%, 82 (45.6%) 가 2.9%, 2.9%, 59 (32.8%), 39 (21.7%) 27 (39.1%) 1.5% 가 (4). 24 (34.8%), 18 (26.1%) 3. 임상 경과 및 치료 반응 $(^2=2.37, df=2, p=0.306)(5).$, 12 Y - BOCS (p=0.02).

Table 5. Course of male and female obsessive compulsive disorder patients

| Courses | | | | | |
|---|---------------------------|--------------------------|-------------------------|--|--|
| | ¹ Episodic (%) | ² Chronic (%) | ³ Others (%) | | |
| OCD total cases | 86 (34.3) | 106 (42.7) | 57 (22.9) | | |
| Male | 59 (32.8) | 82 (45.6) | 39 (21.7) | | |
| Female | 27 (39.1) | 24 (34.8) | 18 (26.1) | | |
| 1 - at least one sire, mesoriles interval aversive sentles that | | | | | |

^{1:} at least one circumscribe interval over six months that was completely symptom free after one OCD onset

Chi-square test: 2 =2.37, df=2, p=0.306

Table 6. Treatment responses between male and female patients

| | _ | Y- | -BOCS/CGI score (mean \pm S. | D) |
|------------------------------|--------|------------------|---------------------------------------|--|
| | | Baseline | at 8 th weeks ^a | at 12 th weeks ^a |
| Total (N=249) | Y-BOCS | 29.22 ± 6.29 | 23.43 ± 5.79 | 21.25 ± 6.94 |
| | CGI | 5.4 ± 0.9 | 3.7 ± 0.8 | 2.9 ±0.8 |
| Male ^b (N=180) | Y-BOCS | 28.91 ± 6.33 | 23.45 ± 5.92 | 21.10 ± 7.94 |
| | CGI | 5.5 ± 0.9 | 3.8 ± 0.7 | 3.1 ± 0.8 |
| Femaleb | Y-BOCS | 30.02 ± 6.17 | 23.34 ± 4.99 | 20.59 ± 5.78 |
| (N=69) | CGI | 5.3 ± 0.8 | 3.6 ± 0.8 | 2.8 ± 0.7 |

Repeated measures ANOVA of Y-BOCS scores

(6).

챀

고

가

 $^{^{\}rm 2}$: symptoms were wax and waning without complete remission over 6 months

³: any courses of symptoms that is not a episodic nor chronic but sometimes repeat cycles between exacerbations

^{: *}significant main effect for time (F=2.97, p=0.02), bno significant main effect for gender (F=0.18, p=0.29), and no significant interaction effect between time and gender (F=0.000, p=0.989)

| , 3) | , | | 12 | |
|---------------------------------------|-----------------|----------------------------|----------------------|---------------------|
| 가 | , | | | 가 |
| 가 가 기 | + | | | |
| . (orbitofrontal cortex) | | | | |
| . ¹⁹⁾ 가 , | 가 | | 가 | · 가 |
| , , , , , , , , , , , , , , , , , , , | 가 . 가 | Bogetto 36.9 | , ¹⁾ 가 | 32.1 28.37 37.12 |
| 가 . 가 | 6,8,9,11,12) | 19 |).42 | |
| | 가 . | 7) 12 Zohar ²⁰⁾ | | |
| (monoaminergic transporter) | 가 (receptor) | Zoriai | , , | . , |
| (serotonin marker) | .15) | 21,22) | | • |

306

(serotonin marker)

(corpus callosum),²³⁾ (axon) (myelinization) ,²⁴⁾ preoptic area 가 가 약 요 (neuromodulatory effect) 연구목적 : (D2), 5-HT2, NMDA, GABA 26 - 28) 가 (serotonin transporter gene) 방 법: 1998 2002 8 가 가 가 (SRI) 249 (physiology)가 가 . Y - BOCS CGI 가 가 12 결 과: 12~40%가 29 - 32) 39% 33) 가 12 가 가 결 론: 34) 가 가 가 중심 단어: 가 참고문헌 가 1) Bogetto F, Venturello S, Albert U, Maina G, Ravizza L. Genderrelated clinical differences in obsessive-compulsive disorder. Eur Psychiatry 1999;14:434-441.

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington D.C., American Psychiatric Press; 1994.
- 3) Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, et al. The cross national epidemiology of obsessivecompulsive disorder. J Clin Psychiatry 1994; Suppl 55:5-10.
- 4) Castle DJ, Deale A, Marks IM. Gender differences in obsessive compulsive disorder. Aust NZ J Psychiatry 1995;29:114-117.
- Rasmussen SA, Tsuang MT. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 1986;143:317-322.
- 6) Lensi P, Cassano GB, Correddu G, Ravagli S, Kunovac JL, Akiskal HS. Obsessive-Compulsive Disorder: familial developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. Br J Psychiatry 1996: 169:101-107.
- 7) Nestadt G, Bienvenu OJ, Cai G, Samuels J, Eaton WW. *Incidence of obsessive-compulsive disorder in adults. J Nerv Ment Dis* 1998;186:401-406.
- Noshirvani HF, Kasvikis Y, Marks IM, Tsakiris F, Monteriro Wo. Gender-divergent aetiological factors in obsessive-compulsive disorder. Br J Psychiaty 1991; 158:260-263.
- 9) Ronchi P, Abruzzese M, Erzegovesi S, Diaferia G, Sciuto G, Bellodi L. The epidemiology of obsessive-compulsive disorder in an Italian population. Eur Psychiatry 1992;7:53-59.
- Bland RC, Newman SC, Orn H. Epidemiology of Psychiatric disorders in the elderly in Edmonton. Acta Psychiatr Scand 1988; 338 (suppl):64-71.
- Marks IM, Fears, Phobias and Rituals. New York: Oxford University Press; 1987.
- Rachman S, Hodgson RL. Obsessions and compulsions. Englewood Cliffs: Prentice-Hall: 1980.
- Fahy TA, Oscar A, Marks I. History of eating disorders in female patients with obsessive-compulsive disorders. Int J Eating Disord 1993;14:439-443.
- 14) Perugi G, Akiskal HS, Pfanner C, Presta S, Gemignani A, Milanfrachi A, et al. The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J Affect Dis 1997:46:15-23.
- Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44:839-850.
- 16) Mundo E, Bareggi SR, Pirola R, Bellodi L. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable. Biol Psyhiatry 1999;45:290-294.
- 17) Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1022.

- 18) Guy W, Bonato RR. CGI. Clinical Global Impressions In: Chase C, editor: Manual of the ECDEU Assessment Battery; 1970. p.1-19.
- 19) Goldman PS, Crawford HT, Stokes LP, Rosvold HE. Sexdependent behavioral effects of cerebral cortical lesions in the developing rhesus monkey. Science 1974: 186:540-542.
- Zohar J, Gross-Isseroff R, Hermesh H, Weizman A. Is there sexual dimorphism in obsessive-compulsive disorder? Neurosci Biobeh Rev 1999;23:845-849.
- 21) Beyer C. Estrogen and the developing mammalian brain. Anat Embryol 1999;199:379-390.
- Hutchison JB, Wozniak A, Beyer C, Karolczak M, Hutchison RE. Steroid metabolism enzymes in the determination of brain gender. J Steroid Biochem Mol Biol 1999:69:85-96.
- 23) Kawata M. Roles of steroid hormones and their receptors in structural organization in the nervous system. Neurosci Res 1995;24:1-46
- 24) Aboitiz F, Rodriguez E, Olivares R, Zaidel E. Age-related changes in fibre composition of the human corpus callosum: sex differences. Neuroreport 1996;7:1761-1764.
- 25) Swaab DF, Fliers E. A sexually dimorphic nucleus in the human brain-a review of the literature. Fortschritte der Neurologie-Psychiatrie FDN 1996;64:382-389.
- 26) Sumner BEH, Fink G. Oestradiol-17B in its positive feedback mode significantly increases 5-HT2a receptor density in the frontal, cingulated and piriform cortex of the female rat. J Physiol 1995;483:52.
- 27) FinK G, Sumner B, McQueen JK, Wilson H, Rose R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998;25:764-765.
- 28) Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor and X and B MRNA in the rat central nervous system. J Compr Neurol 1997;388:507-525.
- Pollitt J. Natural history of obsessional states. Br Med J 1957; 9:133-140.
- Ingram IM. Obsessional illness in mental hospital patients. J Ment Science 1961;107:382-402.
- 31) Lo WH. A follow-up study of obsessional neuritics in Hong Kong Chinese. Br J Psychiatry 1967;113:823-832.
- 32) Diaz SF, Grush LR, Sichel DA, Cohen LS. Obsessive-compulsive disorder in pregnancy and the puerperium. In: Pato MT, Steketee G, editors. OCD across the life cycle. Washington, DC: American Psychiatric Press; 1997. p.97-112.
- Neziroglu F, Anemone R, Yaryura-Tobias J. Onset of obsessivecompulsive disorder in pregnancy. Am J Psychiatry 1992;149: 947-950.
- 34) Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, et al. The role of central oxytocin in obsessive-compulsive disorder and related normal behavior. Psychoneuroendocrinology 1994;19:723-749.